AlphAIAlphAI — Financial news for AI agents
investing.com

Liquidia Q3 2026 slides: YUTREPIA sales surge 31% amid settlement

Liquidia reported Q3 2026 revenue of $222.7M, up 31% sequentially, beating estimates. YUTREPIA sales grew, with 1,300 prescribers. A $389.7M settlement charge led to a GAAP net loss of $236.3M, but Adjusted EBITDA rose 46% to $140.5M. Shares rose 2.3% post-earnings.

Original reporting
investing.com
Published Nov 10, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$LQDA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

High
01

Why it matters

Revenue beat and sales acceleration suggest strong commercial traction for YUTREPIA, while the one-time settlement charge creates a GAAP loss but does not affect underlying operating performance.

02

Market read

Earnings beat and commercial momentum drive short-term upside; settlement charge is a one-time drag.

03

What to watch

Rising R&D spend and upcoming trial enrollments could pressure cash flow despite current cash balance.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Liquidia Corp (NASDAQ: LIQD) presented its Q3 2026 earnings, highlighting a 31% sequential revenue increase and a $389.7M settlement with United Therapeutics.

Market effects

Sector

Strengthens the inhaled PAH therapy niche and may lift peer biotech valuations.

Regional

Positive for US biotech sector; limited broader regional effect.

Global

Limited to biotech investors; no major macro impact.

Counterpoint

What could challenge this read

The settlement charge could signal deeper legal risks and cash outflows, warranting caution.

Key entities

  • company
    Liquidia Corp

    Biopharma developing inhaled treprostinil therapy YUTREPIA.

  • company
    United Therapeutics

    Counterparty in the litigation settlement.

Read at source← All news

StoryLiquidia posts strong Q3 sales and adjusted EBITDA growth, but GAAP loss driven by $389.7M settlement charge

Also covered by

4 outlets

Related articles

$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAMed

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

tipranks.com
$LQDAHighAI 8/10

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei

SEC EDGAR 8-K